Prominent players in the South Korea Angina Market | Insights & Market Overview 2026

Prominent players in the South Korea Angina Market

South Korea Angina Market is curated by a combination of major global players and domestic producers, each vying for a higher market share through product innovation and promotion of sustainable practices. Major companies in the market include AstraZeneca, Pfizer, Hanmi Pharmaceutical, and Chong Kun Dang Pharmaceutical.

South Korea Angina Market Overview

According to 6Wresearch, the South Korea angina market is poised for development, determined by its versatile applications across the healthcare sector, including cardiology, emergency medicine, and chronic disease management. The market is influenced by the rising demand for natural and patient-centric treatment methods, as consumers focus towards effective oral therapies and life-saving interventions in personal care and home-based recovery.

Generally, angina products are specialized medical tools designed to manage the symptoms and underlying causes of chest pain resulting from reduced blood flow to the heart. These products appear as nitrate sprays, beta-blockers, calcium channel blockers, or advanced drug-eluting stents and are used extensively in clinical and homecare applications due to their myocardial oxygen demand reduction properties.

Competitive Landscape

The competitive landscape of the South Korea angina industry is specified by the presence of several global players, regional producers, and emerging companies. Leading companies have a significantly higher market share due to their longstanding presence in the pharmaceutical and medical device industries. They invest greatly towards research and development (R&D) to innovate and develop smart delivery systems and eco-friendly products to satisfy the increasing consumer demand for improved patient compliance.

Below is a list of leading players operating in the South Korea Angina Market:

1. AstraZeneca Korea

AstraZeneca is a dominant leader, with its portfolio of statins and antiplatelet therapies being widely utilized in cardiology departments across the country.

2. Hanmi Pharmaceutical

Hanmi Pharmaceutical provides essential fixed-dose combination therapies that form the backbone of chronic management for hypertension and angina.

3. Chong Kun Dang (CKD) Pharmaceutical

CKD is a major player in the cardiovascular segment, focusing on advanced calcium channel blockers and nitrate-based treatments.

4. Daewoong Pharmaceutical

Daewoong maintains a strong presence through its innovative beta-blockers and metabolic agents tailored for the aging South Korean population.

5. HK inno. N

HK inno. N is a key player in providing high-efficacy cardiovascular solutions and specialized circulatory system medicines.

6. Boryung Pharmaceutical

Boryung focuses on its flagship ARB-based therapies and combination drugs designed to prevent ischemic heart disease complications.

7. Dong-A ST

Dong-A ST provides critical anti-anginal agents and is a leader in the R&D of novel circulatory system treatments.

8. JW Pharmaceutical

JW Pharmaceutical specializes in high-quality intravenous and oral cardiovascular drugs and is active in distributing specialized heart disease therapies.

9. Yuhan Corporation

Yuhan is a leading manufacturer and distributor that partners with global firms to bring specialized antiplatelet tools and anti-anginal medications.

10. Pfizer Korea

Pfizer is a prominent international distributor that provides a wide range of industry-standard calcium channel blockers and lipid-lowering therapies.

Prominent players in the South Korea Angina Market: FAQs